Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Minerva Neurosciences, Inc. Director's Dealing 2017

Jul 26, 2017

35086_dirs_2017-07-26_383541f5-74c3-4672-a2fa-d4a56b548b87.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Minerva Neurosciences, Inc. (NERV)
CIK: 0001598646
Period of Report: 2017-07-24

Reporting Person: Vandervelpen Nico (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-07-24 Stock Option (Right to Buy) $4.71 D 25000 Disposed 2025-12-03 Common Stock (25000) Direct
2017-07-24 Stock Option (Right to Buy) $4.71 A 25000 Acquired 2018-07-24 Common Stock (25000) Direct
2017-07-24 Stock Option (Right to Buy) $10.20 D 12500 Disposed 2026-06-15 Common Stock (12500) Direct
2017-07-24 Stock Option (Right to Buy) $10.20 A 12500 Acquired 2018-07-24 Common Stock (12500) Direct
2017-07-24 Stock Option (Right to Buy) $10.00 D 12500 Disposed 2027-05-31 Common Stock (12500) Direct
2017-07-24 Stock Option (Right to Buy) $10.00 A 12500 Acquired 2018-07-24 Common Stock (12500) Direct

Footnotes

F1: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 4, 2015 and provides for vesting quarterly over 3 years beginning on December 4, 2015.

F2: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 16, 2016 and provides for vesting in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 16, 2016 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

F3: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 1, 2017 and provides for vesting in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 1, 2017 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.